Physician profile
Casey Daniel Blonde
NPI 1538836028
$2,696.56
in general payments reported to CMS, 2019-2025
14 companies · $1,452 in 2025
The $1,452 reported for 2025 was more than what 90% of Psychiatric/Mental Health (Registered Nurse) providers received nationally (typical 2025 total: $137).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $1,244 · 2025: $1,452.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,697.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,696.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $840.42 | 2024-2025 | |
| Otsuka America Pharmaceutical, INC. | $530.84 | 2024-2025 | Rexulti, Abilify Maintena, Abilify Mycite |
| Lundbeck LLC | $255.38 | 2024-2025 | Rexulti |
| Vanda Pharmaceuticals INC. | $214.11 | 2024-2025 | Fanapt |
| Supernus Pharmaceuticals, INC. | $184.39 | 2024-2025 | Qelbree |
| Corium, LLC | $141.01 | 2024-2025 | Azstarys |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $123.05 | 2024-2025 | Caplyta |
| Ironshore Pharmaceuticals INC. | $94.49 | 2024 | |
| Teva Pharmaceuticals USA, INC. | $90.97 | 2025 | Austedo Xr |
| Collegium Pharmaceutical, INC. | $63.20 | 2025 | Jornay Pm |
| Vertical Pharmaceuticals, LLC | $58.09 | 2024-2025 | Relexxii |
| Alkermes, INC. | $37.51 | 2024-2025 | Lybalvi, Aristada |
| Takeda Pharmaceuticals U.S.A., INC. | $34.69 | 2024-2025 | Trintellix |
| Tris Pharma INC | $28.41 | 2024-2025 | Dyanavel Xr |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Casey Blonde listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.